An exchange traded fund indexed to biotechnology stocks has pulled back about 10% from its all-time reached last month as the sector cools after leading the market higher through much of 2012.

Reuters Graphics The second half of 2023 is more likely to see a significant step-up in biotech IPOs instead of the first half, as markets await further clarity on potential rate cuts, analysts said.

Women in biotech, please, correct me if I’m wrong, and tell me about it at luke@timmermanreport.com. Data is cool and all, but it takes time to convert into real medical knowledge There's a ...

Cadence Design Systems unveiled on Wednesday a new supercomputer based on chips from Nvidia that will speed up its software offerings for everything from designing chips to jets to new drugs.